Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Ankylosing Spondylitis Drug market report explains the definition, types, applications, major countries, and major players of the Ankylosing Spondylitis Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Abbott
Wyeth
Eisai
Johnson & Johnson
Takeda
Centocor
Mitsubishi Tanabe
Pfizer
Amgen
Schering-Plough
By Type:
Cimzia
Enbrel
Humira
Remicade
Simponi
Others
By End-User:
Hospitals
Clinics
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Ankylosing Spondylitis Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Ankylosing Spondylitis Drug Outlook to 2028- Original Forecasts
-
2.2 Ankylosing Spondylitis Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Ankylosing Spondylitis Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Ankylosing Spondylitis Drug Market- Recent Developments
-
6.1 Ankylosing Spondylitis Drug Market News and Developments
-
6.2 Ankylosing Spondylitis Drug Market Deals Landscape
7 Ankylosing Spondylitis Drug Raw Materials and Cost Structure Analysis
-
7.1 Ankylosing Spondylitis Drug Key Raw Materials
-
7.2 Ankylosing Spondylitis Drug Price Trend of Key Raw Materials
-
7.3 Ankylosing Spondylitis Drug Key Suppliers of Raw Materials
-
7.4 Ankylosing Spondylitis Drug Market Concentration Rate of Raw Materials
-
7.5 Ankylosing Spondylitis Drug Cost Structure Analysis
-
7.5.1 Ankylosing Spondylitis Drug Raw Materials Analysis
-
7.5.2 Ankylosing Spondylitis Drug Labor Cost Analysis
-
7.5.3 Ankylosing Spondylitis Drug Manufacturing Expenses Analysis
8 Global Ankylosing Spondylitis Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Ankylosing Spondylitis Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Ankylosing Spondylitis Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Ankylosing Spondylitis Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Ankylosing Spondylitis Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Cimzia Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Enbrel Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Humira Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Remicade Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Simponi Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Ankylosing Spondylitis Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Ankylosing Spondylitis Drug Market Analysis and Outlook till 2022
-
10.1 Global Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.2.2 Canada Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.2.3 Mexico Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.2 UK Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.3 Spain Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.4 Belgium Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.5 France Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.6 Italy Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.7 Denmark Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.8 Finland Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.9 Norway Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.10 Sweden Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.11 Poland Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.12 Russia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.3.13 Turkey Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.2 Japan Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.3 India Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.4 South Korea Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.5 Pakistan Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.7 Indonesia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.8 Thailand Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.9 Singapore Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.10 Malaysia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.11 Philippines Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.4.12 Vietnam Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.2 Colombia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.3 Chile Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.4 Argentina Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.5 Venezuela Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.6 Peru Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.5.8 Ecuador Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6.2 Kuwait Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6.3 Oman Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6.4 Qatar Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.7.2 South Africa Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.7.3 Egypt Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.7.4 Algeria Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Ankylosing Spondylitis Drug Consumption (2017-2022)
-
10.8.2 New Zealand Ankylosing Spondylitis Drug Consumption (2017-2022)
11 Global Ankylosing Spondylitis Drug Competitive Analysis
-
11.1 Abbott
-
11.1.1 Abbott Company Details
-
11.1.2 Abbott Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Abbott Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.1.4 Abbott Ankylosing Spondylitis Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Wyeth
-
11.2.1 Wyeth Company Details
-
11.2.2 Wyeth Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Wyeth Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.2.4 Wyeth Ankylosing Spondylitis Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Eisai
-
11.3.1 Eisai Company Details
-
11.3.2 Eisai Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Eisai Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.3.4 Eisai Ankylosing Spondylitis Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Johnson & Johnson
-
11.4.1 Johnson & Johnson Company Details
-
11.4.2 Johnson & Johnson Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Johnson & Johnson Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.4.4 Johnson & Johnson Ankylosing Spondylitis Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Takeda
-
11.5.1 Takeda Company Details
-
11.5.2 Takeda Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Takeda Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.5.4 Takeda Ankylosing Spondylitis Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Centocor
-
11.6.1 Centocor Company Details
-
11.6.2 Centocor Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Centocor Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.6.4 Centocor Ankylosing Spondylitis Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Mitsubishi Tanabe
-
11.7.1 Mitsubishi Tanabe Company Details
-
11.7.2 Mitsubishi Tanabe Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.7.4 Mitsubishi Tanabe Ankylosing Spondylitis Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Pfizer
-
11.8.1 Pfizer Company Details
-
11.8.2 Pfizer Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Pfizer Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.8.4 Pfizer Ankylosing Spondylitis Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Amgen
-
11.9.1 Amgen Company Details
-
11.9.2 Amgen Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Amgen Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.9.4 Amgen Ankylosing Spondylitis Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Schering-Plough
-
11.10.1 Schering-Plough Company Details
-
11.10.2 Schering-Plough Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Schering-Plough Ankylosing Spondylitis Drug Main Business and Markets Served
-
11.10.4 Schering-Plough Ankylosing Spondylitis Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Ankylosing Spondylitis Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Cimzia Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Enbrel Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Humira Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Remicade Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Simponi Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Ankylosing Spondylitis Drug Market Analysis and Outlook to 2028
-
13.1 Global Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.5 France Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.3 India Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Ankylosing Spondylitis Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Ankylosing Spondylitis Drug
-
Figure of Ankylosing Spondylitis Drug Picture
-
Table Global Ankylosing Spondylitis Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Ankylosing Spondylitis Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Cimzia Consumption and Growth Rate (2017-2022)
-
Figure Global Enbrel Consumption and Growth Rate (2017-2022)
-
Figure Global Humira Consumption and Growth Rate (2017-2022)
-
Figure Global Remicade Consumption and Growth Rate (2017-2022)
-
Figure Global Simponi Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Table North America Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure United States Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure Germany Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure France Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure China Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure India Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table South America Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure Brazil Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure Bahrain Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure Nigeria Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Ankylosing Spondylitis Drug Consumption by Country (2017-2022)
-
Figure Australia Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Ankylosing Spondylitis Drug Consumption and Growth Rate (2017-2022)
-
Table Abbott Company Details
-
Table Abbott Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Abbott Ankylosing Spondylitis Drug Product Portfolio
-
Table Wyeth Company Details
-
Table Wyeth Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Wyeth Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Wyeth Ankylosing Spondylitis Drug Product Portfolio
-
Table Eisai Company Details
-
Table Eisai Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Eisai Ankylosing Spondylitis Drug Product Portfolio
-
Table Johnson & Johnson Company Details
-
Table Johnson & Johnson Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Johnson & Johnson Ankylosing Spondylitis Drug Product Portfolio
-
Table Takeda Company Details
-
Table Takeda Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Takeda Ankylosing Spondylitis Drug Product Portfolio
-
Table Centocor Company Details
-
Table Centocor Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Centocor Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Centocor Ankylosing Spondylitis Drug Product Portfolio
-
Table Mitsubishi Tanabe Company Details
-
Table Mitsubishi Tanabe Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mitsubishi Tanabe Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Mitsubishi Tanabe Ankylosing Spondylitis Drug Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Pfizer Ankylosing Spondylitis Drug Product Portfolio
-
Table Amgen Company Details
-
Table Amgen Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Amgen Ankylosing Spondylitis Drug Product Portfolio
-
Table Schering-Plough Company Details
-
Table Schering-Plough Ankylosing Spondylitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Schering-Plough Ankylosing Spondylitis Drug Main Business and Markets Served
-
Table Schering-Plough Ankylosing Spondylitis Drug Product Portfolio
-
Figure Global Cimzia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Enbrel Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Humira Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Remicade Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Simponi Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Table North America Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure China Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Ankylosing Spondylitis Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Ankylosing Spondylitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
